Schrödinger is the scientific leader in developing state-of-the-art chemical simulation software for use in pharmaceutical, biotechnology, and materials research.

難溶性薬物の放出メカニズムを解明する – ASD研究の新たなアプローチ | Modelling amorphous solid dispersion (ASD) release mechanisms OCT 15, 2025 | AbbVie と Schrödinger のエキスパートが …

Our mission is to improve human health and quality of life by transforming the way therapeutics and materials are discovered.

Our physics-based computational platform integrates differentiated solutions for predictive modeling, data analytics, and collaboration to enable rapid exploration of chemical space.

We are leveraging our computational platform and massive computing power to advance our proprietary programs both independently and in collaboration with leading biotech and pharmaceutical companies.

Jan 9, 2026 · Schrödinger, Inc. (Nasdaq: SDGR) today announced a collaboration with Lilly TuneLab™, a platform launched by Eli Lilly and Company (Lilly) designed to accelerate drug discovery and …

Headquartered in New York City, Schrödinger has multiple offices around the world including the USA, the UK, Germany, India, and Japan.

Jan 12, 2026 · Schrdinger, Inc. (Nasdaq: SDGR) provided an update on its progress across the business in 2025 and announced its strategic priorities for 2026. The company is continuing to focus on …

Schrödinger is excited to be participating in the NERDG 2026 conference taking place on March 30th in Groton, Connecticut. Join us for a presentation by Shiva Sekharan, Global Portfolio Leader of …

Aug 14, 2025 · Schrödinger, Inc. (Nasdaq: SDGR) today announced the discontinuation of the clinical development program for SGR-2921, its CDC7 inhibitor, which was being evaluated in a Phase 1 …